Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Vick

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|April 13, 2016
Programming the immune checkpoint to treat hematologic malignanciesEric Vick, Daruka Mahadevan
Oncotarget|December 17, 2017
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategyShariful Islam, Eric Vick, Bryan Huber, et al.
Haematologica|April 27, 2023
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammationTomoya Muto, Callum S Walker, Puneet Agarwal, et al.
Oncotarget|July 24, 2015
The antidiabetic compound 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from Averrhoa carambola L., demonstrates significant antitumor potential against human breast cancer cellsYing Gao, Renbin Huang, Yixuan Gong, et al.
Blood|May 12, 2023
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AMLJoshua Bennett, Chiharu Ishikawa, Puneet Agarwal, et al.
Cancers|October 13, 2021
Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PatientsKate Clancy, Chelsea S Hamill, W Quinn O'Neill, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|April 13, 2016
Programming the immune checkpoint to treat hematologic malignanciesEric Vick, Daruka Mahadevan
Oncotarget|December 17, 2017
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategyShariful Islam, Eric Vick, Bryan Huber, et al.
Haematologica|April 27, 2023
Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammationTomoya Muto, Callum S Walker, Puneet Agarwal, et al.
Oncotarget|July 24, 2015
The antidiabetic compound 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from Averrhoa carambola L., demonstrates significant antitumor potential against human breast cancer cellsYing Gao, Renbin Huang, Yixuan Gong, et al.
Blood|May 12, 2023
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AMLJoshua Bennett, Chiharu Ishikawa, Puneet Agarwal, et al.
Cancers|October 13, 2021
Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PatientsKate Clancy, Chelsea S Hamill, W Quinn O'Neill, et al.
Pageof 1